Table 3 Descriptives of IPF-AE patients never and ever treated with steroids and immunosuppressants before hospital admission

Sex

15 male / 9 female

6 male / 6 female

9 male / 3 female

p = 0.400

Age (years)

69.5 (52–82)

71.5 (52–80)

68 (52–82)

p = 0.270

Smoking (p-y)

40 (0–110)

35 (0–60)

42.5 (0–110)

p = 0.515

BMI

25.35 (17.6–32)

24.93 (22.49–31.2)

27.4 (17.6–32)

p = 0.081

Emphysema

4 yes, 20 no

1 yes, 11 no

3 yes, 9 no

p = 0.590

PH

4 yes, 6 no, 6 NA

3 yes, 6 no, 2 NA

3 yes, 4 no, 4 NA

p = 1

FVC (lt)

2.01 (0.59–3.17)

1.9 (0.59–2.43)

2.52 (1.34–3.17)

p = 0.056

FVC % predicted

63 (27.1–94)

53.15 (27.1–81.8)

65.1 (34.3–94)

p = 0.646

FEV₁ (lt)

1.57 (0.56–2.78)

1.43 (0.56–1.88)

1.86 (1.25–2.78)

p = 0.055

FEV₁ % predicted

60.6 (31.3–79)

53.5 (31.3–70.2)

70.2 (41.7–79)

p = 0.074

TLC (lt)

3.21 (2.44–4.64)

2.84 (2.44–4.23)

4.04 (2.84–4.64)

p = 0.007

TLC % predicted

57.2 (38.7–86.9)

52.2 (38.7–86.9)

57.5 (55.9–75)

p = 0.101

DLCO (ml/min/mmHg)

2.68 (1.69–4.49)

2.68 (1.69–4.49)

3.13 (1.9–3.85)

p = 0.619

DLCO % predicted

38.3 (19.6–54.3)

37.4 (19.6–54.3)

38.3 (24–38.9)

p = 0.865

6MWD (meters)

272 (150–492)

271.5 (153–492)

272 (150–441)

p = 0.932

Disease duration

43 (0–96)

49 (0–77)

34 (6–96)

p = 0.744

Pattern of GGO in HRCT

5 peripheral, 8 multifocal, 8 diffuse, 3 NA

3 peripheral, 5 multifocal, 3 diffuse, 1 NA

2 peripheral, 3 multifocal, 5 diffuse, 2 NA

p = 0.444

NIMV

2

0

2

p = 0.478

Mechanical ventilation

6

0

6

p = 0.014

LTOT

6

3

3

p = 0.640

PO₂/fiO₂

163.5 (66–314.29)

181.25 (116.6–266.6)

152.95 (66–314.29)

p = 0.378

BAL performed

6 yes, 18 no

3 yes, 9 no

3 yes, 9 no

p = 0.640